Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Synergy among agents inhibiting granulocyte aggregation

D E Hammerschmidt, P J Flynn, P A Coppo

|June 1, 1982

Summary

This study found that combining methylprednisolone and ibuprofen showed synergistic effects in reducing myocardial infarction size in cats. This combination therapy may offer a novel approach for treating cardiovascular diseases by targeting granulocyte function.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).

Journal of neuro-oncology·2019

Same author

Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).

Journal of neuro-oncology·2019

Same author

The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Same author

Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study.

Breast cancer research and treatment·2014

Same author

SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.

British journal of cancer·2013

Same author

A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.

Clinical genitourinary cancer·2013

Area of Science:

Immunology
Pharmacology
Cardiovascular Medicine

Background:

Complement (C)-stimulated granulocytes (polymorphonuclear cells, PMNs) play a role in diseases like shock and myocardial infarction (MI).
Corticosteroids inhibit PMN responses but their clinical use for these conditions is limited.
Investigating synergistic combinations of agents targeting PMN function is crucial for developing effective therapies.

Purpose of the Study:

To investigate the synergistic effects of methylprednisolone (MP), ibuprofen (IBU), and betahistine (BH) in inhibiting PMN aggregation in vitro.
To evaluate the combined efficacy of MP and IBU in reducing myocardial infarction size in an in vivo animal model.

Main Methods:

In vitro assessment of PMN aggregation inhibition by MP, IBU, and BH, individually and in combination.

Related Experiment Videos

In vivo study using a feline model of coronary artery ligation to measure myocardial infarction size after treatment with MP and IBU.

Main Results:

Significant synergy (3.4-fold) was observed when MP, IBU, and BH were used simultaneously to inhibit PMN aggregation.
MP and IBU demonstrated additive effects in inhibiting superoxide generation and directed migration of PMNs.
In vivo, the combination of MP and IBU, at individually ineffective doses, reduced myocardial infarction size by 42%.

Conclusions:

Synergistic interactions between MP, IBU, and BH suggest they target distinct cellular mechanisms in PMN function.
Preliminary in vivo data support the potential clinical application of combined therapies targeting PMN function for cardiovascular diseases like MI.